Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) shot through the roof today, up 30% as of this filming. In the video below, Fool health-care analyst David Williamson discusses news of some great phase 3 trial results for the company's drug Pimavanserin, which treats psychosis in patients with Parkinson's disease. David tells investors how good the results were, and what advantages this drug candidate could have over its competition if it reaches FDA approval.
David Williamson owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Keys for Acadia Pharmaceuticals to Succeed in 2018
Acadia CEO Stephen Davis outlines the path to success for the biotech at the J.P. Morgan Healthcare Conference.
Here's How Acadia Pharmaceuticals Crushed It in 2017
Nuplazid's sales are soaring, but Acadia's stock price hasn't responded in kind. Is that mismatch creating a buying opportunity for investors?
3 Stocks That Turned $8,000 Into at Least $138,000 in 5 Years
Some stocks have outperformed the market, and then there's MGP Ingredients, Acadia Pharma, and Netflix.